Pharmafile Logo
Pharmafocus logo
Advanced Search

Internal Medicine

Showing 7 posts of 7 posts found.

University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma

October 30, 2024
Research and Development Edinburgh, Internal Medicine, Microbiology, acquisitions, biopharma, inhibitors

Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (KMO) inhibitors – has been …

News
cancer_drip_2

Chiesi announces phase 3 results from enzyme-replacement study

October 29, 2024
Research and Development Internal Medicine, Rare Diseases, chiesi Global rare diseases, clinical trials, pharma, rare diseases

Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug …

News

Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis

October 21, 2024
Research and Development CHMP, EMA, EU, Internal Medicine, gene

Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European Union (EU) by the European …

News

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA

August 1, 2024
Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma

Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …

News
Press release

Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University

July 31, 2024
Clinical Research, Medical Communications, Research and Development Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research

Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s …

News

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024
Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism

Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …

News

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

September 14, 2023
Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025